Clinically, a pragmatic interpretation is that PDE5 inhibitors can be considered first-line for adult men with SCI-related erectile dysfunction when not contraindicated, while devices or injections may be considered when PDE5 inhibitors are ineffective or not tolerated, with explicit counselling that patient-centred outcomes and longer-term relational benefits remain uncertain. This evidence concerns the gene PDE5A and erectile dysfunction.